Sign in

ADMP on NASDAQ

Adamis Pharmaceuticals Corporation

Pharmaceutical company in San Diego, United States, founded in 20061

In its 2023 annual report the company says: “Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.”63 It employed 131 people in 2019.1 Its shares trade on NASDAQ under the symbol ADMP.1

Price unavailable

Last updated Oct 21, 2026.

Overview

2006Founded1

Compare with PureTech Ventures, SPRUCE BIOSCIENCES, INC. or InMed Pharmaceuticals Inc., or pick any stock.

  • TickerADMP on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego1
  • Websitewww.adamispharmaceuticals.com
  • Legal formDelaware corporation1
  • Incorporated inDE4
  • Business address11682 El Camino Real, Suite 300, San Diego, Ca 921304
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • LEI549300EBMD9JZ2H87I373
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O GKL Registered Agents, Inc., 19901 Dover, United States3
  • Registered withDivision of Corporations, Department of State, 37749923

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-30.1%Gross margin5
-526.9%Operating margin5
-556.7%Net margin5
115.3%Revenue growth, 20225
-$26.6MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue21¢$6.2M
  • Research and development35¢$10.4M
  • Selling, general and admin44¢$13.2M
  • Income tax0¢$2.0K

Out of $4.8M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$4.8M in 2022−27% since 2016
0$10.0M$20.0M$30.0M2016: $6.5M$6.5M20162017: $13.1M$13.1M2017+102%2018: $15.1M$15.1M2018+15%2019: $22.1M$22.1M2019+47%2020: $16.5M$16.5M2020−25%2021: $2.2M$2.2M2021−87%2022: $4.8M$4.8M2022+115%
Gross profit10789115-$1.4M in 2022
-$5.0M0$5.0M$10.0M2016: $1.6M$1.6M20162017: $5.7M$5.7M2017+249%2018: $5.3M$5.3M2018−6%2019: $6.6M$6.6M2019+25%2020: -$3.6M-$3.6M20202021: -$4.7M-$4.7M2021+31%2022: -$1.4M-$1.4M2022−69%
Operating income10789115-$25.1M in 2022−1% since 2016
-$40.0M-$30.0M-$20.0M-$10.0M02016: -$25.2M-$25.2M20162017: -$24.8M-$24.8M2017−2%2018: -$39.5M-$39.5M2018+59%2019: -$29.4M-$29.4M2019−26%2020: -$36.3M-$36.3M2020+24%2021: -$32.1M-$32.1M2021−12%2022: -$25.1M-$25.1M2022−22%
Net income10789115-$26.5M in 2022+36% since 2016
-$60.0M-$40.0M-$20.0M02016: -$19.4M-$19.4M20162017: -$25.5M-$25.5M2017+31%2018: -$39.0M-$39.0M2018+53%2019: -$27.5M-$27.5M2019−29%2020: -$49.4M-$49.4M2020+80%2021: -$45.8M-$45.8M2021−7%2022: -$26.5M-$26.5M2022−42%
Fiscal year2016201720182019202020212022
Revenue$6.5M6$13.1M7$15.1M8$22.1M9$16.5M9$2.2M5$4.8M5
Cost of revenue$4.9M10$7.4M7$9.8M8$15.5M9$6.3M11$6.9M5$6.2M5
Gross profit$1.6M10$5.7M7$5.3M8$6.6M9-$3.6M11-$4.7M5-$1.4M5
Research and development$9.7M10$7.5M7$18.8M8$10.4M9$8.0M11$11.3M5$10.4M5
Selling, general and admin$17.1M10$22.8M7$25.9M8$25.3M9$20.1M11$16.1M5$13.2M5
Operating income-$25.2M10-$24.8M7-$39.5M8-$29.4M9-$36.3M11-$32.1M5-$25.1M5
Interest$214.4K10$231.3K7$157.8K8$123.3K9$4.9K11$6.6K11
Income before tax-$34.6M5-$26.2M5
Income tax-$4.6M10-$339.4K7-$369.3K8$8.7K9$2.4K11$7965$2.0K5
Net income-$19.4M10-$25.5M7-$39.0M8-$27.5M9-$49.4M11-$45.8M5-$26.5M5
Earnings per share-$1.196-$0.325-$0.185
Earnings per share (diluted)-$1.196-$0.325-$0.185
Shares (weighted, basic)144.2M shares5149.9M shares5
Shares (weighted, diluted)144.2M shares5149.9M shares5

Compare Adamis Pharmaceuticals Corporation with another company

Corporate structure

Adamis Pharmaceuticals Corporation sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Adamis Pharmaceuticals Corporation

  • INTRACOASTAL CAPITAL, LLC Filed SC 13G/A on Adamis Pharmaceuticals Corporation, latest Feb 6, 2024 (2 filings since Aug 10, 2023)
  • Versi Group LLC Filed SC 13D/A on Adamis Pharmaceuticals Corporation, latest Sep 26, 2023 (2 filings since Jun 5, 2023)
  • Adamis Pharmaceuticals Corporation San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Adamis Pharmaceuticals Corporation reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$5.2M5 Dec 31, 2022$4.5M5 Dec 31, 2021+15.2%
Construction in progress$744.4K5 Dec 31, 2022$993.8K5 Dec 31, 2021−25.1%
Accumulated depreciation$4.7M5 Dec 31, 2022$3.2M5 Dec 31, 2021+46.6%
Property and equipment, net$1.3M5 Dec 31, 2022$2.3M5 Dec 31, 2021−44.8%
Operating-lease assets (leased space)$317.6K5 Dec 31, 2022$650.5K5 Dec 31, 2021−51.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.1M5 Dec 31, 2022$23.2M5 Dec 31, 2021−95.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$1.2M5 Dec 31, 2022$418.6K5 Dec 31, 2021+195.9%
Raw materials$709.5K5 Dec 31, 2022$32.0K5 Dec 31, 2021+2117.4%
Work in process$261.7K5 Dec 31, 2022$386.6K5 Dec 31, 2021−32.3%
Finished goods$267.6K5 Dec 31, 2022$892.9K11 Dec 31, 2020−70.0%

Leadership

Who has led Adamis Pharmaceuticals Corporation, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dennis J. Carlo Phd.2009–2022
  2. Eddie Wabern Glover2016–2019
  3. Ebrahim Versi2023

President

  1. Dennis J. Carlo Phd.2009–2022

Chief financial officer

  1. Robert O. Hopkins2009–2021
  2. David C. Benedicto2021–2022
  3. Seth Cohen2023
2010201520202025
Board members and other officers (20)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorRichard C. Williams named Jul 7, 202239

Employees over time

  • 20191311

Former names

  • Adamis Pharmaceuticals CorpApr 8, 2009 to Sep 1, 20234
  • CELLEGY PHARMACEUTICALS INCJul 9, 1996 to Apr 3, 20094

Timeline

  1. Jul 1, 20248-K Completed an acquisition or sale; Executive or director change40
  2. Feb 7, 20248-K Listing notice or transfer41
  3. Feb 5, 20248-K Bankruptcy or receivership; Regulation FD disclosure; Other events42
  4. Jan 31, 20248-K Shareholder vote43
  5. Jan 23, 20248-K Change to shareholders' rights; Bylaws or fiscal year changed44
  6. Jan 3, 20248-K Regulation FD disclosure45
  7. Jan 3, 20248-K Shareholder vote; Other events46
  8. Dec 21, 20238-K Ended a material agreement; Other events47
  9. Dec 4, 20238-K Shareholder vote; Other events48
  10. Nov 28, 20238-K Ended a material agreement; Other events49
  11. Nov 15, 20238-K Shareholder vote; Other events50
  12. Nov 14, 20238-K Results of operations51
  13. May 30, 2023New chief executive Ebrahim Versi becomes CEO15
  14. Apr 14, 2016New chief executive Eddie Wabern Glover becomes CEO16
  15. Apr 13, 2009New chief executive Dennis J. Carlo Phd. becomes CEO17
  16. 2006Founded Founded1

Calendar

When it reported results

  1. Nov 14, 2023Reported quarterly or annual results51
  2. Aug 21, 2023Reported quarterly or annual results52
  3. May 15, 2023Reported quarterly or annual results53
  4. Mar 16, 2023Reported quarterly or annual results54
  5. Nov 14, 2022Reported quarterly or annual results55
  6. Aug 10, 2022Reported quarterly or annual results56
  7. May 16, 2022Reported quarterly or annual results57
  8. Mar 31, 2022Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

155 filings to the SEC since October 2021: 5 annual reports, 9 quarterly reports, 65 major events, 25 insider forms, 4 large holders, 2 private raises, 45 other. The latest 20:

  1. Jul 1, 20248-K CURRENT REPORT EDGAR
  2. Mar 21, 202425-NSE EDGAR
  3. Feb 7, 20248-K CURRENT REPORT EDGAR
  4. Feb 6, 2024SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G EDGAR
  5. Feb 5, 20248-K CURRENT REPORT EDGAR
  6. Jan 31, 20248-K CURRENT REPORT EDGAR
  7. Jan 23, 2024DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS EDGAR
  8. Jan 23, 20248-K CURRENT REPORT EDGAR
  9. Jan 3, 2024DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS EDGAR
  10. Jan 3, 20248-K CURRENT REPORT EDGAR
  11. Jan 3, 20248-K CURRENT REPORT EDGAR
  12. Dec 21, 20238-K CURRENT REPORT EDGAR
  13. Dec 4, 2023DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS EDGAR
  14. Dec 4, 20238-K CURRENT REPORT EDGAR
  15. Nov 28, 20238-K CURRENT REPORT EDGAR
  16. Nov 15, 2023DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  17. Nov 15, 2023DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  18. Nov 15, 20238-K CURRENT REPORT EDGAR
  19. Nov 15, 2023DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  20. Nov 14, 20238-K CURRENT REPORT EDGAR

The 155 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 0 buys and 8 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 18, 2022Moss Ronald B.Chief Medical OfficerSale8,199$0.60$4.9KForm 4
Mar 18, 2022Marguglio David J.SVP and Chief Business OfficerSale11,859$0.60$7.1KForm 4
Mar 18, 2022CARLO DENNIS J PHDSale10,490$0.60$6.3KForm 4
Mar 18, 2022Benedicto David C.Chief Financial OfficerSale3,603$0.61$2.2KForm 4
Dec 1, 2021Benedicto David C.Chief Financial OfficerSale13,554$0.79$10.7KForm 4
Dec 1, 2021Moss Ronald B.Chief Medical OfficerSale35,553$0.79$28.1KForm 4
Dec 1, 2021Marguglio David J.SVP and Chief Business OfficerSale50,757$0.79$40.1KForm 4
Dec 1, 2021CARLO DENNIS J PHDSale47,870$0.79$37.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$5.3M 2020–2022
Money received by yearMoney received by year, 2020–2022: $5.3M in all. Private raises (Form D) $300.0K; PPP loans $5.0M.$0$1M$2M$3M$4M2020 · PPP loans: $3.2M20202021 · PPP loans: $1.8M20212022 · Private raises (Form D): $300.0K2022
Figures by year
YearPrivate raises (Form D)PPP loansTotal
2022$300.0K–$300.0K
2021–$1.8M$1.8M
2020–$3.2M$3.2M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. May 25, 2023Filed a private offering of equity61 Form D: 12 investors so far Form D
  2. Jul 5, 2022Raised $300,000 in a private offering of equity39 Form D: 1 investor so far Form D

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA62. Matched to this company by name and state.

  1. Apr 8, 2020$3.2M PPP loan (first draw) from Arvest Bank62To ADAMIS PHARMACEUTICALS CORPORATION, San Diego CA; $3.2M forgiven Aug 6, 2021
  2. Feb 12, 2021$1.8M PPP loan (second draw) from Arvest Bank62To ADAMIS PHARMACEUTICALS CORPORATION, San Diego CA; $1.8M forgiven Sep 29, 2021

SEC filer profile

How Adamis Pharmaceuticals Corporation is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDMK PHARMACEUTICALS Corp2
  • CIK0000887247
  • Employer ID (EIN)82-04297272
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address11682 El Camino Real, Suite 300, San Diego, CA 921302
  • Phone(858) 997-24002
  • Shares outstanding10,102,050 as of Nov 13, 202314
  • Public float$74.4M as of Jun 30, 20225
  • On EDGAR sinceFeb 13, 19962
  • Filings1,210 in all: 8-K (299), 4 (284), 10-Q (75), SC 13D/A (35), 3 (31), 424B3 (29), DEFA14A (27), SC 13G/A (27)2
    All 67 form types

    10-K (24), 5 (24), SC 13G (24), EFFECT (23), CORRESP (21), DEF 14A (21), POS AM (19), S-3 (19), 424B5 (17), S-8 (17), 10-K/A (16), 8-K/A (15), NT 10-Q (13), UPLOAD (12), SC 13D (10), D (9), S-3/A (9), 10QSB (8), S-1/A (8), 10-Q/A (7), NT 10-K (7), PRE 14A (7), 4/A (5), REGDEX (5), 3/A (4), ARS (4), DEFR14A (4), S-1 (4), 425 (3), CT ORDER (3), PREC14A (3), S-4/A (3), 10KSB (2), 424B2 (2), 424B4 (2), DEFC14A (2), NT 10-Q/A (2), PREM14A (2), S-8 POS (2), SB-2/A (2), 10-KT (1), 25-NSE (1), 424B1 (1), 5/A (1), 8-A12B (1), 8-A12G/A (1), CERTNAS (1), DEFM14A (1), DFAN14A (1), FWP (1), PRER14A (1), PX14A6G (1), RW (1), S-1MEF (1), S-2 (1), S-2/A (1), S-3MEF (1), S-4 (1), SB-2 (1)

  • Latest filingsAnnual report (10-K) Mar 16, 2023
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Jul 7, 2022
    Latest 8-K (8-K) Jul 1, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63